Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study.
about
Rituximab for treating inhibitors in people with inherited severe hemophiliaTreatment for preventing bleeding in people with haemophilia or other congenital bleeding disorders undergoing surgeryRituximab for treating inhibitors in children with hemophiliaTreatment for preventing bleeding in people with congenital bleeding disorders undergoing surgerySwitching treatments in haemophilia: is there a risk of inhibitor development?FVIII inhibitors: pathogenesis and avoidanceAspects of prophylactic treatment of hemophiliaSIPPET: methodology, analysis and generalizability.Current and evolving features in the clinical management of haemophiliaReview of antihemophilic factor injection for the routine prophylaxis of bleeding episodes and risk of joint damage in severe hemophilia A.Validity of assessing inhibitor development in haemophilia PUPs using registry data: the EUHASS project.Increased prevalence of inhibitors in Hispanic patients with severe haemophilia A enrolled in the Universal Data Collection database.Factor VIII brand and the incidence of factor VIII inhibitors in previously untreated UK children with severe hemophilia A, 2000-2011Inhibitor development in previously treated hemophilia A patients: a systematic review, meta-analysis, and meta-regression.The IL-10 polarized cytokine pattern in innate and adaptive immunity cells contribute to the development of FVIII inhibitors.Hemophilia care in India: a review and experience from a tertiary care centre in uttar pradesh.Design of the INHIBIT trial: preventing inhibitors by avoiding 'danger', prolonging half-life and promoting tolerance.Patient data meta-analysis of Post-Authorization Safety Surveillance (PASS) studies of haemophilia A patients treated with rAHF-PFM.Treatment of hemophilia: a review of current advances and ongoing issuesDiagnostic evaluation of our patients with hemophilia A: 17-year experienceSuccessful Phenotype Improvement following Gene Therapy for Severe Hemophilia A in Privately Owned Dogs.Diagnostic and therapeutic challenges of intracranial hemorrhage in neonates with congenital hemophilia: a case report and review.A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A managementNew treatments in hemophilia: insights for the clinician.Issues in pediatric haemophilia careInhibitor development in haemophilia B: an orphan disease in need of attention.Intracranial haemorrhage in haemophilia A and B.Primary prophylaxis in children with haemophilia.Quantitation of anti-factor VIII antibodies in human plasma.High rate of spontaneous inhibitor clearance during the long term observation study of a single cohort of 524 haemophilia A patients not undergoing immunotolerance.Inhibitor development.Achievements, challenges and unmet needs for haemophilia patients with inhibitors: Report from a symposium in Paris, France on 20 November 2014.Recombinant factor VIII in the management of hemophilia A: current use and future promise.Inhibitors in mild/moderate haemophilia A: two case reports and a literature review.Risk factors for high-titer inhibitor development in children with hemophilia A: results of a cohort study.Antihemophilic factor (recombinant) plasma/albumin-free method for the management and prevention of bleeding episodes in patients with hemophilia ARisk factors for inhibitor formation in haemophilia: a prevalent case-control study.Bayesian approach to the assessment of the population-specific risk of inhibitors in hemophilia A patients: a case study.Platelet gene therapy corrects the hemophilic phenotype in immunocompromised hemophilia A mice transplanted with genetically manipulated human cord blood stem cells.The history and evolution of the clinical effectiveness of haemophilia type a treatment: a systematic review.
P2860
Q24186623-C796451A-EA4F-4F3E-898A-8B61A6063F38Q24188177-12970A4E-7D78-401D-9DD9-6374F0B91740Q24197700-98A8E035-EEA0-4D30-A19F-118C719B0272Q24202459-F147F0CE-0ACD-428A-BE83-BD9F64F482D6Q27001016-2D703637-4577-49C8-BAAC-1E2FD60980B9Q27027224-248FAD7A-DC3A-4D7A-802B-36A70D94D589Q28078562-60F97AF7-5C05-4CD9-A2F0-09ACC68260DAQ30235225-C039A174-68D0-4202-96AE-AC90D9DBABB1Q33708976-079A10BF-CEB8-45EA-B3FB-EB4824989A69Q33715399-98B04658-FFD8-4308-A344-EEB57B2A42E0Q34063824-A93ABC23-6EFA-48DF-9451-1E7609D0082BQ34129239-61E5ACF9-1EEA-47DB-AB87-1B1E0A6D1F2BQ34580100-2AE87DE0-BBA0-4F38-BEE9-3502B4DC13A8Q34784564-DB9D2C97-E017-4240-A9EC-2FD8B4DEBA8AQ35046770-22935FBF-28DA-405C-8AFC-CCCB4615F3C3Q35163225-70188A6A-22FD-430B-BC27-381C66B6F368Q35168244-4F484C54-A505-4043-A7CB-1264BB0F91C6Q35209354-3704F15A-D2A7-49DA-BC35-A576F854CBEEQ35683781-AFB1EFBD-2125-44F1-9722-988080117CAAQ35913693-813CB360-4F17-4A45-A3E5-CCA9AF023856Q35969194-46BD104D-E550-42E1-B223-45B8542F3A42Q36250900-05C47324-5EC1-4160-B9A5-D143F0F90DB9Q36369011-6B8ED4C8-6CD6-4BBC-A9A6-C27970EEC86DQ36612681-DCEF8C85-A87A-42CD-B2E4-84FBD9F1E6B7Q36835166-B94C8F12-87A6-4370-9EF5-EB366EA49D2FQ36872038-1FC58A96-9160-4C41-A972-AD607416E123Q37032896-74F4D39D-247B-4B8A-91D5-53485603B976Q37119644-04B974A5-18E0-4A88-AF13-54FAF9DC5235Q37129689-4B54F958-14DD-4F2C-AF10-304E5CECD83CQ37153668-F5072A68-4803-4BC5-B27A-EF73BA9C336DQ37176486-D8DC327F-B37C-485E-B98D-77D286CA437FQ37185097-E52FF70A-4BB2-4D3B-AB64-3FD0F5F9F053Q37230340-754476D9-F067-4965-9057-758E11DEDEE0Q37244126-7AAB3368-2442-41FB-9BD6-296F41EA3834Q37253340-FE386347-8134-41F6-BF9F-199F3F5A4A1CQ37303186-E97A2BF5-3A58-43F0-B9C9-B1AFDDA3002FQ37325682-76299091-2297-40BF-A2D4-9103CC7966B5Q37381565-84767748-3FC7-4192-9A29-F223FF122B8BQ37489033-39322309-5672-4C40-9749-2C759633A399Q37578173-E84EB272-49DD-46E1-8C58-4971288FB87C
P2860
Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Treatment-related risk factors ...... lia A: the CANAL cohort study.
@en
Treatment-related risk factors ...... lia A: the CANAL cohort study.
@nl
type
label
Treatment-related risk factors ...... lia A: the CANAL cohort study.
@en
Treatment-related risk factors ...... lia A: the CANAL cohort study.
@nl
prefLabel
Treatment-related risk factors ...... lia A: the CANAL cohort study.
@en
Treatment-related risk factors ...... lia A: the CANAL cohort study.
@nl
P921
P1433
P1476
Treatment-related risk factors ...... ilia A: the CANAL cohort study
@en
P2093
H Marijke van den Berg
Samantha C Gouw
P304
P356
10.1182/BLOOD-2006-11-056291
P407
P577
2007-02-08T00:00:00Z